Atezolizumab

Generic Name
Atezolizumab
Brand Names
Tecentriq
Drug Type
Biotech
Chemical Formula
-
CAS Number
1380723-44-3
Unique Ingredient Identifier
52CMI0WC3Y
Background

Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...

Indication

Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions
Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
Associated Therapies
-

A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2017-06-07
Last Posted Date
2024-11-01
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1000
Registration Number
NCT03178552
Locations
🇺🇸

UC Davis; Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

Rocky Mountain Cancer Center, Denver, Colorado, United States

🇺🇸

SCRI Florida Cancer Specialists South, Fort Myers, Florida, United States

and more 174 locations

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2017-06-07
Last Posted Date
2021-11-04
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
21
Registration Number
NCT03179943
Locations
🇺🇸

USC Norris Hospital and Clinics, Los Angeles, California, United States

🇺🇸

Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

First Posted Date
2017-06-02
Last Posted Date
2024-11-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
80
Registration Number
NCT03174197
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors

First Posted Date
2017-05-31
Last Posted Date
2023-07-27
Lead Sponsor
Exelixis
Target Recruit Count
1732
Registration Number
NCT03170960
Locations
🇺🇸

Exelixis Clinical Site #51, Newport Beach, California, United States

🇪🇸

Exelixis Clinical Site #94, Oviedo, Asturias, Spain

🇺🇸

Exelixis Clinical Site #10, Boston, Massachusetts, United States

and more 121 locations

Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer

First Posted Date
2017-05-24
Last Posted Date
2024-10-14
Lead Sponsor
Oslo University Hospital
Target Recruit Count
68
Registration Number
NCT03164993
Locations
🇩🇰

Vejle Sygehus, Vejle, Denmark

🇩🇰

Rigshospitalet, Copenhagen, Denmark

🇳🇴

Oslo University Hospital, Oslo, Norway

and more 2 locations

NCT Neuro Master Match - N²M² (NOA-20)

First Posted Date
2017-05-18
Last Posted Date
2023-09-28
Lead Sponsor
University Hospital Heidelberg
Target Recruit Count
228
Registration Number
NCT03158389
Locations
🇩🇪

University Hospital Mainz, Neurosurgery, Mainz, Germany

🇩🇪

University Hospital Heidelberg, Neurology Clinic, Heidelberg, Germany

🇩🇪

University Hospital Frankfurt, Neurooncology, Frankfurt am Main, Germany

and more 10 locations

A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2017-05-16
Last Posted Date
2020-05-18
Lead Sponsor
BioLineRx, Ltd.
Target Recruit Count
1
Registration Number
NCT03154827
Locations
🇺🇸

Medical College of Wisconsin/Froedtert Hospital, Milwaukee, Wisconsin, United States

🇺🇸

The University of Texas - Md Anderson Cancer Center - Leukemia Center, Houston, Texas, United States

🇨🇿

Fakultni Nemocnice Brno / University Hospital Brno Interni Hematologicka A Onkologicka Klinika / Internal Hematology and Oncology Clinic, Brno, Czechia

and more 9 locations

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2017-05-11
Last Posted Date
2024-11-08
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
382
Registration Number
NCT03148418
Locations
🇺🇸

Florida Cancer Specialists - Fort Myers (Broadway), Fort Myers, Florida, United States

🇺🇸

Angeles Clinic & Rsch Inst, Los Angeles, California, United States

🇺🇸

Northwestern University; Robert H. Lurie Comp Can Ctr, Chicago, Illinois, United States

and more 170 locations

AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2017-05-10
Last Posted Date
2022-07-19
Lead Sponsor
The Netherlands Cancer Institute
Target Recruit Count
23
Registration Number
NCT03147040
Locations
🇳🇱

Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands

🇳🇱

Antoni van Leeuwenhoek, Amsterdam, Netherlands

🇳🇱

Maastricht University Medical Center, Maastricht, Netherlands

and more 1 locations
© Copyright 2024. All Rights Reserved by MedPath